Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof.

Provided herein are polypeptides that include one or more β-tricalcium phosphate (βTCP)-binding sequence(s) and uses thereof.

The application is related to a method for preparing an induced osteogenesis formulation, the method comprises the following steps: (1) a human dental matrix is decalcified; (2) then an exogenous active protein BMP, i.e. bone morphogenetic protein is added to the decalcified dental matrix, resulting in the induced osteogenesis formulation

The application is related to a method for preparing an induced osteogenesis formulation, the method comprises the following steps: (1) a human dental matrix is decalcified; (2) then an exogenous active protein BMP, i.e. bone morphogenetic protein is added to the decalcified dental matrix, resulting in the induced osteogenesis formulation

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.

Fusion proteins containing a half-life extension protein, a linker, and a GDF15 protein are described. Also described are nucleic acids encoding the fusion proteins, recombinant cells thereof, compositions comprising the fusion proteins, and methods of using the fusion proteins for treating or preventing metabolic diseases, disorders or conditions.

Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Recombinant proteins that comprise a bone morphogenic protein 2 backbone onto which was grafted a Müllerian-inhibiting substance type II receptor binding region of the Müllerian-inhibiting substance protein are provided. These proteins bind to this receptor on the surface of epithelial cancer cells, and induce apoptosis of such cells. These proteins are useful, for example, in the treatment of cancers such as ovarian, uterine, endometrial, fallopian tube, breast, prostate, and lung cancers.

Compositions and methods are described for a polymer hydrogel created by a cycloaddition reaction between an azide and an alkyne that proceeds rapidly without catalyst to produce the polymer hydrogel in less than ninety seconds. The polymer hydrogel can be used in in vivo applications for the localized delivery of therapeutic agent in aqueous solutions. An example of therapeutic delivery of a protein in a mouse model is demonstrated.